Fortress Companies

Home » Fortress companies » caelum biosciences

Caelum Biosciences*

Caelum Biosciences, Inc. (“Caelum”), founded by Fortress Biotech, is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Caelum’s lead asset, CAEL-101 (mAb 11-1F4), is a novel antibody for the treatment of patients with amyloid light chain (“AL”) amyloidosis. Phase 1a/1b data presented at the American Society of Hematology’s 59th Annual Meeting in December 2017 support CAEL-101’s potential to be a safe and well-tolerated therapy that promotes amyloid resolution. CAEL-101 has received Orphan Drug Designation from the U.S. Food and Drug Administration as a therapeutic agent for patients with AL amyloidosis, and as a radio-imaging agent in amyloidosis. 

For more information, please visit

*Caelum Biosciences, Inc. is an entity which was founded by Fortress and in which Fortress still maintains a large minority ownership position.